PARP1 and ovarian cancer: These findings provide a novel clinically applicable therapeutic strategy using CBL0137 to sensitize HR-proficient SSRP1-high ovarian cancer patients to PARP inhibitors thereby broadening the scope of PARPi irrespective of BRCA1/2 mutation status and HR status.